SEC Form 4 · accession 0001214659-26-011541
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter E. Boyd
Officer — Chief People Officer
Period of report
Sep 9, 2026
Accepted (ET)
Sep 10, 2026 · 9:21 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001398733
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 9, 2026 | X | 2,293 | $0.96 | A | 284,024 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (Right to Buy) | $0.96 | Sep 9, 2026 | X | 2,293 | D | Dec 8, 2022 | Jun 8, 2027 | Common Stock | 2,293 | 0 | D |
Explanation of responses
- F1Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.